Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00160654
Previous Study | Return to List | Next Study

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00160654
Recruitment Status : Completed
First Posted : September 12, 2005
Results First Posted : August 19, 2020
Last Update Posted : August 19, 2020
Sponsor:
Information provided by (Responsible Party):
UCB Pharma

Brief Summary:

Community based study assessing safety and efficacy of levetiracetam in partial onset seizures.

The optimal dose in daily clinical practice will be used.


Condition or disease Intervention/treatment Phase
Epilepsy, Partial Drug: Levetiracetam Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 251 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Open-label, Multi-center, Community-based Trial in Asia Studying the Safety and Efficacy of Keppra™ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.
Actual Study Start Date : November 24, 2003
Actual Primary Completion Date : December 12, 2006
Actual Study Completion Date : December 12, 2006


Arm Intervention/treatment
Experimental: Levetiracetam
Subjects received open-label Levetiracetam.
Drug: Levetiracetam
  • Pharmaceutical form: oral tablets
  • Concentration: 500 mg
  • Route of administration: Oral use
Other Name: Keppra




Primary Outcome Measures :
  1. Number of Patients With Adverse Events (AEs) [ Time Frame: From Baseline until Safety visit (two weeks after last dose; up to Week 18) ]
    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.


Secondary Outcome Measures :
  1. Percentage Change From Historical Baseline in Partial (Type I) Seizure Frequency Per Week Over the Treatment Period [ Time Frame: Week 16, compared to Baseline ]

    Percentage change from baseline in partial (Type I) seizure frequency over the treatment period standardized to 1 week period.

    Type I Partial (focal, local) seizure frequency per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.

    A negative value in percent change from historical baseline indicates a decrease in partial (type I) seizure frequency from historical baseline.


  2. Percentage Change From Historical Baseline in Total (Type I+II+III) Seizure Frequency Per Week Over the Treatment Period [ Time Frame: Week 16, compared to Baseline ]

    Percentage change from baseline in total (type I+II+III) seizure frequency over the treatment period standardized to 1 week period.

    Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.

    A negative value in percent change from historical baseline indicates a decrease in total (type I+II+III) seizure frequency from historical baseline.


  3. Percentage of Participants With 50% Response in Seizure Frequency Per Week at Week 16 [ Time Frame: Week 16, compared to Baseline ]

    50% response in seizure frequency per Week is defined as >=50% reduction in seizure frequency from Baseline.

    Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.


  4. Percentage of Participants With 100% Response in Seizure Frequency Per Week at Week 16 [ Time Frame: Week 16, compared to Baseline ]

    100% response in seizure frequency per Week is defined as 100% reduction in seizure frequency from Baseline.

    Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.


  5. Percentage of Patients With Categorized Change From Baseline in Severity of Illness [ Time Frame: Baseline, Week 16 ]
    The overall change in the severity of the subject's illness, compared to the subject's condition prior to the levetiracetam intake, was assessed by the Investigator using Investigator's Global Evaluation Scale (IGS). Categories are as following: Marked improvement; Moderate improvement; Slight improvement; No change; Slight worsening; Moderate worsening; Marked worsening.

  6. Retention Rate at Week 16 [ Time Frame: Week 16 ]
    Retention rate, defined as the number of subjects who were still on levetiracetam at Visit 5 (Week 16) or on the day before divided by the number of subjects in the ITT population.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized.
  • Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1.
  • Use of one (1), but no more than two (2) concomitant marketed antiepileptic drugs (AEDs) at the time of trial entry.

Exclusion Criteria:

  • Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months.
  • Presence of known pseudoseizures within the last year.
  • Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors.
  • Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00160654


Locations
Show Show 29 study locations
Sponsors and Collaborators
UCB Pharma
Investigators
Layout table for investigator information
Study Director: UCB Cares UCB (+1 844 599 2273)
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: UCB Pharma
ClinicalTrials.gov Identifier: NCT00160654    
Other Study ID Numbers: N01036
First Posted: September 12, 2005    Key Record Dates
Results First Posted: August 19, 2020
Last Update Posted: August 19, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by UCB Pharma:
Epilepsy
Partial Onset Seizures
Keppra
Levetiracetam
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Levetiracetam
Anticonvulsants
Nootropic Agents